Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study NCT05092958 Advanced Bladde...
Advanced Renal ...
Advanced Ureter...
Advanced Urethr...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Stage III Bladd...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Avelumab
Biospecimen Col...
Bone Scan
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI) View Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma NCT03513952 Advanced Bladde...
Advanced Ureter...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Glycosylated Re...
Laboratory Biom...
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI) View Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy NCT04963153 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Erdafitinib
18 Years - National Cancer Institute (NCI) View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma NCT04940299 Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Malignant Solid...
Metastatic Blad...
Metastatic Blad...
Metastatic Lung...
Metastatic Mela...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Uret...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Lung ...
Stage IVB Lung ...
Unresectable Me...
Ipilimumab
Nivolumab
Tocilizumab
18 Years - M.D. Anderson Cancer Center View Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer NCT02567409 Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Stage IV Bladde...
Berzosertib
Cisplatin
Gemcitabine Hyd...
18 Years - National Cancer Institute (NCI) View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate NCT03582475 Bladder Small C...
Castration-Resi...
Metastatic Blad...
Metastatic Uret...
Prostate Carcin...
Prostate Neuroe...
Prostate Small ...
Stage III Bladd...
Stage III Prost...
Stage III Ureth...
Stage IV Bladde...
Stage IV Prosta...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Ureter Small Ce...
Urothelial Carc...
Carboplatin
Cisplatin
Docetaxel
Etoposide
Pembrolizumab
18 Years - Jonsson Comprehensive Cancer Center View Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy NCT04637594 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
18 Years - Alliance for Clinical Trials in Oncology View Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma NCT04848519 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Pembrolizumab
Propranolol Hyd...
Nivolumab
Avelumab
18 Years - Emory University View Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression NCT04953104 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center View Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer NCT03237780 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI) View Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Advanced Urothe...
Metastatic Blad...
Metastatic Pros...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Stage IV Bladde...
Stage IV Prosta...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Ur...
Bevacizumab
Cisplatin
Gemcitabine Hyd...
Laboratory Biom...
Placebo Adminis...
18 Years - National Cancer Institute (NCI) View Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer NCT03237780 Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI) View Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224 Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Refractory Blad...
Refractory Rena...
Refractory Uret...
Refractory Uret...
Refractory Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Biospecimen Col...
Bone Scan
Computed Tomogr...
Docetaxel
Eribulin Mesyla...
Gemcitabine Hyd...
Magnetic Resona...
Paclitaxel
Sacituzumab Gov...
18 Years - National Cancer Institute (NCI) View Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy NCT03935347 Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Unresectable Re...
Unresectable Ur...
Cyclophosphamid...
Fludarabine
Fludarabine Pho...
Pembrolizumab
Autologous Tumo...
Aldesleukin
18 Years - Roswell Park Cancer Institute View